News

Vivoryon Therapeutics Showcases Breakthrough Results for DKD

Vivoryon Therapeutics Showcases Breakthrough Results for DKD

Vivoryon Therapeutics N.V. Unveils Key Meta-analysis Results

Halle (Saale) / Munich, Germany – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7), a pioneering clinical-stage biotechnology firm, is dedicated to developing innovative small molecule therapies targeting inflammatory and fibrotic disorders, particularly chronic kidney diseases. The company has shared pivotal meta-analysis data regarding its lead therapeutic candidate, varoglutamstat, at a significant educational congress.

Significant Presentation at Renowned Congress

At the recent congress of the European Renal Association, Vivoryon highlighted the positive outcomes from the Phase 2 trial program of varoglutamstat. CEO Frank Weber expressed profound excitement over presenting these findings, sharing that the improvements observed in kidney function (eGFR) demonstrated the potential of varoglutamstat to positively impact patients suffering from kidney diseases.

Key Findings from the Meta-analysis

According to the presentation, varoglutamstat, recognized as a first-in-class glutaminyl cyclase (QPCT/L) inhibitor, has shown remarkable anti-inflammatory and anti-fibrotic properties. The results from two independent Phase 2 studies—VIVIAD and VIVA-MIND—indicated a significant and clinically meaningful enhancement in kidney function among older patients. This correlation between treatment with varoglutamstat and improved eGFR was verified across both studies as well as through subsequent meta-analysis observations.

Clinical Implications of Results

The data illustrated that statistically noteworthy differences between varoglutamstat and placebo appeared as early as week 24 and continued to show sustained results up until week 96. Notably, participants with diabetes experienced an even greater effect size, a significant detail for the medical community working with diabetic patients.

Future Directions for Varoglutamstat

Looking ahead, Vivoryon plans to initiate a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, specifically those with diabetes and chronic kidney disease classified as stage 3b/4. The trial aims to evaluate the efficacy of varoglutamstat on eGFR while exploring its impact on proteinuria and additional kidney-specific markers.

Presentation Overview and Details

The presentation occurred in Vienna, where Dr. Frank Weber discussed pivotal aspects of the study:

  • Date: June 6, 2025
  • Presentation Time: 8:15 am CEST
  • Title: varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies
  • Venue: Vienna, Austria

Company Background: Vivoryon Therapeutics N.V.

Vivoryon operates with an passionate vision to revolutionize treatments for inflammatory and fibrotic disorders affecting the kidney. With varoglutamstat being its flagship program, the company is committed to enhancing patient outcomes by altering the trajectory of severe kidney conditions through its innovative approaches in medicine.

Contact Details for Further Information

For inquiries, Vivoryon invites potential investors and interested parties to reach out to:

Investor Contacts
Dr. Manuela Bader, Director of Investor Relations & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu

Frequently Asked Questions

What is the main focus of Vivoryon Therapeutics?

Vivoryon Therapeutics primarily develops medicines targeting inflammatory and fibrotic kidney disorders.

What is varoglutamstat?

Varoglutamstat is an innovative QPCT/L inhibitor showing promise in improving kidney function.

What were the results of the recent studies presented?

The studies demonstrated significant improvements in kidney function among patients treated with varoglutamstat.

What are the next steps for Vivoryon?

The company plans to initiate a Phase 2b trial focusing on diabetic kidney disease.

How can interested parties contact Vivoryon?

Inquiries can be directed to the Investor Relations department via the provided email.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Air Canada-CAE Scholarship Drives Women in Aviation

Updated Category News Views 51

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Continue Reading
FirstLight Home Care Reaches 300 Locations Milestone

Updated Category News Views 0

FirstLight Celebrates a Major Milestone FirstLight Home Care just hit a big milestone, reaching a whopping 300 locations. That's not just a feather in their cap; it's a sign that their approach to senior care is resonating with communities across the map. The company is kicking off a celebration tour, cleverly dubbed the Best Days Tour, highlighting each step forward with...

Continue Reading
Grinnell Poll Unveils Shifting Confidence, Crisis Fears

Updated Category News Views 0

Confidence in Fair Elections Climbs Amid Turmoil You know what, there are days when you just gotta chuckle at the way things unfold. Take the latest Grinnell College Poll: it tells us Americans are feeling more upbeat about their votes being counted right. Now, that's a breath of fresh air in a space that's been clogged with doubt for way too long. Pessimism on...

Continue Reading
Step into Fear: Dead by Daylight in Moreno Valley

Updated Category News Views 8

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

Continue Reading
Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Updated Category News Views 23

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

Continue Reading
California Exodus: Companies Flee Amid Wealth Tax Fears

Updated Category News Views 114

Businesses Escaping the Golden State Proposition 40—the looming specter over California's business landscape. This so-called billionaire tax has stirred quite the storm, and from where I'm sitting, it's no surprise folks are heading for the exits. Cummings & Cummings Law reports a jaw-dropping 12-fold increase in companies scooting out of California and making a beeline...

Continue Reading
Royce Micro-Cap Trust: Navigating Small-Cap Waves

Updated Category News Views 6

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 40

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Data Centers Drive Surge in Power and Cooling Demand

Updated Category News Views 0

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Continue Reading
Sodium Silicate Market To Hit $7.4B by 2031

Updated Category News Views 53

What's Fueling the Market's Climb? I tell ya, sodium silicate might not be a household name, but it's trekking upwards with a clear purpose. By 2031, this market's expected to touch $7.4 billion from $6 billion in 2026 at a neat 4.4% CAGR. For an old-school trader like me, that's the kind of steady growth that catches my eye. The driving factors? Well, it’s more than...

Continue Reading

Top 5 Most Recently Viewed Articles

Resmed Partners for Rugby Tour Promoting Sleep Health Awareness

Updated Category News Views 214

Resmed's Role in the British & Irish Lions Tour Resmed (NYSE: RMD, AUST: RMD.AX), a health technology leader specializing in sleep and respiratory care, has proudly partnered with the Qatar Airways British & Irish Lions Tour in Australia. This collaboration aims to address sleep health, an essential yet often overlooked aspect of athletic performance and overall...

Continue Reading
Cedar Capital Corporation Announces Securities Acquisition Update

Updated Category News Views 239

Cedar Capital Corporation's Acquisition of Securities Cedar Capital Corporation is making waves with its recent move in the market, as it has filed an important early warning report regarding its acquisition of securities in 0749116 B.C. Ltd., previously known as Baroyeca Gold & Silver Inc., and now operating under the name Terra Rossa Gold Ltd. This significant...

Continue Reading
CJ 4DPLEX Achieves Stunning Growth with Innovative Formats

Updated Category News Views 409

CJ 4DPLEX Experiences Unprecedented Growth in 2025 4DX and SCREENX Formats Drive a 47% Growth Rate This Year CJ 4DPLEX, a leading figure in premium cinema technologies, recently reported an extraordinary performance during the first half of 2025. This year has witnessed its innovative 4DX and SCREENX formats achieving an impressive 47% year-over-year growth in domestic...

Continue Reading
Teva’s Innovations in Schizophrenia Treatment: UZEDY and TEV-749 Data Revealed

Updated Category News Views 751

Teva Pharmaceuticals Announces Exciting Data on Schizophrenia Treatments In the world of mental health, Teva Pharmaceuticals is stepping up with groundbreaking advancements that aim to make a difference for those affected by schizophrenia. At a recent conference, Teva shared impressive data on their innovative treatments, highlighting UZEDY® (risperidone) and TEV-'749...

Continue Reading
Insights into Recent Auction Results of Treasury Bonds

Updated Category News Views 171

Exploring Treasury Bonds Auction Results Treasury bonds play an essential role in the financial landscape, and understanding their auction results can provide insights into market sentiment and investor behavior. Recently, the auction for RIKS 50 0915 yielded significant data that reflects the current trends and investor confidence in the economy. In this article, we will...

Continue Reading